{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:54Z","timestamp":1787999874150,"version":"build-2784847793"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejca.2022.11.023","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T21:36:06Z","timestamp":1669412166000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-613X","authenticated-orcid":false,"given":"Shungo","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1253","authenticated-orcid":false,"given":"Satoru","family":"Mitsuboshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2022.11.023_bib1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.023_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2022-000291","article-title":"Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan","volume":"4","author":"Yoshikawa","year":"2022","journal-title":"BMJ Neurol Open"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.023_bib3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejca.2022.11.023_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.668765","article-title":"Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances","volume":"12","author":"Khouri","year":"2021","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.023_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2169\/internalmedicine.8387-21","article-title":"Lambert-eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer","volume":"61","author":"Kunii","year":"2022","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.023_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000494078","article-title":"Lambert-eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2018","journal-title":"Case Rep Neurol"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.023_bib7","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1007\/s10072-021-05557-9","article-title":"Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient","volume":"42","author":"Duplaine","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ejca.2022.11.023_bib8","doi-asserted-by":"crossref","unstructured":"Lee JH, Baek SK, Han JJ, Kim HJ, Lee YA, Yoo D, et\u00a0al., Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study, J Chemother. Online ahead of print. doi: 10.1080\/1120009X.2022.2073162.","DOI":"10.1080\/1120009X.2022.2073162"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.023_bib9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp-2020-323212","article-title":"Encephalitis as an immune-related adverse event","volume":"91","author":"Suzuki","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.023_bib10","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/acn3.51213","article-title":"HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor","volume":"7","author":"Chang","year":"2020","journal-title":"Ann Clin Transl Neurol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:43Z","timestamp":1760733523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":10,"alternative-id":["S0959804922017683"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}